Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular investigational varicella vaccine plus Priorix versus subcutaneous Varivax plus Priorix in healthy toddlers
2024-518840-18-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Dec 2025
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of GSKVX000000025896, measles, mumps and rubella vaccine (live) and varicella virus vaccine live in chickenpox, measles, mumps and 1 more (2 arms), sponsored by GSK. Primary endpoints: Seroresponse to varicella-zoster virus glycoprotein E at Day 43, Anti-varicella-zoster virus glycoprotein E IgG concentration at Day 43 and 2 more. Planned start Dec 2025; status: authorised.
02
Drugs
GSKVX000000025896measles, mumps and rubella vaccine (live)varicella virus vaccine live
03
Conditions
chickenpoxmeaslesmumpsrubella
Beyond the preview
Go deeper on 2024-518840-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518840-18-00.